Vise Technologies Inc. Acquires New Position in Stryker Corporation $SYK

Vise Technologies Inc. bought a new position in Stryker Corporation (NYSE:SYK) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 11,844 shares of the medical technology company’s stock, valued at approximately $3,729,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SYK. Gables Capital Management Inc. purchased a new position in Stryker during the second quarter valued at approximately $25,000. Godfrey Financial Associates Inc. purchased a new stake in shares of Stryker in the fourth quarter worth $26,000. Sankala Group LLC bought a new stake in shares of Stryker during the 4th quarter valued at $26,000. United Financial Planning Group LLC bought a new stake in shares of Stryker during the 3rd quarter valued at $27,000. Finally, Atlas Capital Advisors Inc. purchased a new position in shares of Stryker during the 4th quarter valued at $27,000. Institutional investors own 77.09% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on SYK. Evercore set a $350.00 price target on Stryker in a research note on Monday, July 6th. JPMorgan Chase & Co. lowered their price objective on Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. Barclays dropped their price objective on Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research note on Monday, May 4th. Needham & Company LLC cut their target price on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Finally, Truist Financial lifted their target price on Stryker from $330.00 to $340.00 and gave the company a “hold” rating in a research note on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $386.28.

Stryker Stock Performance

SYK opened at $327.97 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The stock has a market capitalization of $125.80 billion, a price-to-earnings ratio of 33.99, a PEG ratio of 2.17 and a beta of 0.76. The company has a fifty day moving average of $326.64 and a 200 day moving average of $332.66. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $396.86.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. During the same quarter in the previous year, the company earned $3.13 EPS. The business’s quarterly revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, sell-side analysts forecast that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker’s payout ratio is currently 36.48%.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 50,000 shares of Stryker stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total value of $17,005,000.00. Following the sale, the director owned 2,251,375 shares of the company’s stock, valued at $765,692,637.50. The trade was a 2.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Debra King sold 826 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the sale, the insider directly owned 6,210 shares in the company, valued at $2,088,423. This trade represents a 11.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 665,370 shares of company stock worth $216,238,501. Corporate insiders own 4.60% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.